Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy, Rong Zhou, Cynthia A. Moylan, Juan P. Frías, Naim Alkhouri, Meena B. Bansal, Seth J. Baum, Brent A. Neuschwander‐Tetri, Rebecca Taub, Sam E. Moussa
Topics & Concepts
PlaceboSteatohepatitisMedicineInternal medicineDouble blindPhase (matter)Physical therapyFatty liverAlternative medicineDiseasePathologyPhysicsQuantum mechanicsLiver Disease Diagnosis and TreatmentLiver Disease and TransplantationDrug-Induced Hepatotoxicity and Protection